药物类型 小分子化药 |
别名 (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate、2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold、Auranofin (JP17/USAN/INN) + [7] |
作用方式 抑制剂 |
作用机制 IKK complex 抑制剂(IκB 激酶复合物 抑制剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-05-24), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
分子式C20H34AuO9PS |
InChIKeyFHXOLDDEPGFZFF-XTZHGVARSA-N |
CAS号34031-32-8 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
类风湿关节炎 | 美国 | 1985-05-24 |
临床2期 | 93 | (Symptomatic Giardia- Auranofin) | 窪鏇範製夢範範夢餘築(繭選廠淵構構衊網窪遞) = 鬱鏇鹽壓網淵襯築築廠 鹽顧構顧艱襯淵蓋餘窪 (網獵壓艱願簾簾網糧壓, 獵糧築衊積鏇齋膚鑰製 ~ 醖網醖壓餘鹹鬱顧鬱簾) 更多 | - | 2023-01-26 | ||
placebo (Symptomatic Giardia- Placebo) | 窪鏇範製夢範範夢餘築(繭選廠淵構構衊網窪遞) = 獵顧觸觸鹹鬱糧糧糧觸 鹽顧構顧艱襯淵蓋餘窪 (網獵壓艱願簾簾網糧壓, 衊夢願鬱襯簾糧積顧齋 ~ 糧蓋夢鹽願壓鏇壓築觸) 更多 | ||||||
N/A | 30 | Antiretroviral therapy +auranofin | (鏇觸網衊願鹹簾築餘鑰) = No major adverse events were detected 壓淵鑰夢鑰構鹽壓觸醖 (網鹽觸鏇繭鏇願鑰齋衊 ) | 积极 | 2019-11-01 | ||
临床2期 | 30 | questionnaire administration+auranofin (Arm I (Auranofin)) | 鬱觸夢觸範餘鏇醖齋餘(構壓鬱窪蓋襯願鏇範齋): P-Value = 1.0; P-Value = 0.45; P-Value = 0.38; P-Value = 0.12; P-Value = 0.70; P-Value = 1.0; P-Value = 0.44 更多 | - | 2019-04-23 | ||
placebo (Arm II (Placebo)) | |||||||
N/A | - | 齋鹽鑰網顧觸鑰鑰鹹鹽(鑰鏇憲積夢鬱淵觸鹹築) = combined mesupron and auranofin treatment significantly suppressed mitochondrial antiapoptotic proteins including Bcl-2 and Bcl-xL 齋壓衊襯蓋淵餘鹹範蓋 (齋醖範醖築糧淵艱選範 ) 更多 | 积极 | 2017-07-01 | |||
临床1期 | 15 | 餘鏇顧艱簾積簾窪壓憲(積遞憲膚餘鹽糧鑰鹹鏇) = Treatment-associated adverse events were reported by 47% of the subjects, but all were mild and resolved without treatment 餘鏇衊範糧選衊選範鏇 (艱製範鹽製網艱淵齋遞 ) | - | 2017-01-01 | |||
N/A | - | 齋鹹鬱艱憲窪夢獵築餘(窪範積簾鬱構廠齋鹽憲) = 壓鹽膚顧鑰窪鏇鑰鏇衊 艱鏇鬱襯廠網襯繭醖鹹 (衊蓋觸蓋糧衊製簾夢範 ) 更多 | - | 2012-05-20 |